drugset / Trial / NCT04466254
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To assess the efficacy and safety of the combination of CPGJ602 and chemotherapy in subjects with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer.
Timeline
- Start
- 2020-12-07
- Primary completion
- 2021-12-30
- Completion
- 2022-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPGJ602 | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | CPGJ602 | Monoclonal antibody | 325 mg/m2 | Intravenous |
| Comparator | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |